Table 1.

Characteristics of included patients

Male/female, no.	19/11
Age, mean ± SD (range) years	75 ± 14 (35–94)
Body weight, mean ± SD, kg	67.4 ± 19
Body mass index, mean ± SD (range)	23.7 ± 4.5 (15–36)
Patients with body mass index >30, no.	2
Creatinine clearance, mean ± SD, ml min−1	60 ± 25
Patients with creatinine clearance <50 ml min−1, no.	10
Patients with creatinine clearance <30 ml min−1, no.	2
Patients with a diagnosis of hepatic failure, no.	1
Medical conditions
Lone atrial fibrillation, no.	4
Coronary disease, no.	10
Hypertensive heart disease, no.	7
Non-ischaemic dilated cardiomyopathy, no.	5
Other cardiac conditions (valvular disease, cor pulmonale), no.	3
Chronic important noncardiac conditions, no.	19
Amiodarone treatment
Indications:
Atrial fibrillation (maintenance of sinus rhythm), no.	26
Other supraventricular tachycardia, no.	2
Ventricular arrhythmia, no.	2
Current daily maintenance dose, mean ± SD (range), mg	172 ± 41 (75–200)
Total time of treatment, mean ± SD (range), months	36 ± 43 (3–148)
Total cumulated dose, mean ± SD (range), g	205 ± 263 (15–968)
Associated treatments
Digoxin, no.	2
Diuretics, no.	16
β-Blockers, no.	9
Calcium-channel blockers, no.	1*
Statins, no.	7†

^*The patient received amlodipine.

^†Four patients received pravastatin, two simvastatin and one atorvastatin. no., number of patients; SD, standard deviation.